Moneycontrol
HomeNewsBusinessEarningsQ2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance
Trending Topics

Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance

Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.

November 12, 2018 / 08:18 IST
Story continues below Advertisement

Moneycontrol News

Aurobindo Pharma, which reports its results on November 12, is likely to see muted growth in its US business. Multiple brokerages expect profit to be in the range of Rs 600-780 crore.

Story continues below Advertisement

Further, high R&D cost is likely to affect financials, one brokerage house wrote in its report.

Here is a gist of what multiple brokerages are forecasting for its September quarter show.